ERBB2 and breast cancer: Finally, the OlympiA trial found that adjuvant olaparib improved three-year disease-free survival from 77% to 86% in BRCA carriers with early-stage, high-risk HER2-negative BC compared to placebo, and led to a significant improvement in OS (HR, 0.68; 98.5% CI 0.47–0.97; p < 0.01) [10].